Warm congratulations on the inclusion of Nuocan Health Innovation's drugs in key recommendations of various CSCO cancer guidelines

The Chinese Society of Clinical Oncology (CSCO) recently released the 2026 edition of its series of cancer diagnosis and treatment guidelines. Orelabrutinib (InnoCare Pharma's InnoCore), tislelizumab (Minocore), and zanubrutinib (InnoCine) have secured several significant recommendations in the 'CSCO Lymphoma Diagnosis and Treatment Guidelines 2026 Edition', 'CSCO Malignant Hematological Disease Diagnosis and Treatment Guidelines 2026 Edition', and 'CSCO Head and Neck Tumor Diagnosis and Treatment Guidelines 2026 Edition' due to their robust clinical evidence and excellent efficacy and safety.

In the 'CSCO Lymphoma Diagnosis and Treatment Guidelines 2026 Edition', orelabrutinib and tislelizumab achieved upgraded and new recommendations across multiple lymphoma subtypes, further solidifying InnoCare Pharma's leading position in the field of hematological malignancy treatment:

Orelabrutinib has been elevated toa Level I recommendation for first-line treatment across all populations with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)；

Orelabrutinib continues to maintain itsLevel I recommendation for second-line treatment of marginal zone lymphoma (MZL), while the combination regimen of orelabrutinib and rituximabNewly included as a Level II recommendation for first-line treatment of MZL, making Orelabrutinib thefirst and only BTK inhibitor to be included in the CSCO guidelines for first-line treatment recommendations for MZL；

· As a BTK inhibitor, Orelabrutinib continues to maintain its Level II recommendation for initial treatment of mantle cell lymphoma (MCL) and Level I recommendation for relapsed/refractory MCL treatment

· Based on clinical research data from the Orelabrutinib combined with high-dose methotrexate and rituximab (R-OM) regimen, BTK inhibitors combined with high-dose methotrexate have been included as a Level II recommendation for first-line treatment of primary central nervous system lymphoma (PCNSL)

· Tafasitamab combined with lenalidomide regimenupgraded to a Level I recommendation for second-line and above treatment of diffuse large B-cell lymphoma (DLBCL)；

· Tafasitamab combined with rituximab and lenalidomide regimennewly included as a Level I recommendation for relapsed/refractory follicular lymphoma treatment。

In the 'CSCO Guidelines for Diagnosis and Treatment of Hematologic Malignancies 2026 Edition,' Orelabrutinib has been upgraded to a Level I recommendation for first-line treatment of CLL/SLL, reaffirming its clinical advantages in first-line treatment of CLL/SLL.

In the 'CSCO Head and Neck Tumor Diagnosis and Treatment Guidelines 2026 Edition,' Zolactinib has been newly included as a Level II recommendation for the treatment of recurrent/metastatic salivary gland cancer. This is also the first time that Zolactinib has been recommended by the CSCO guidelines since its approval for marketing in December 2025.

The series of tumor diagnosis and treatment guidelines issued by the Chinese Society of Clinical Oncology (CSCO) represent the authoritative standard for clinical tumor diagnosis and treatment in China. These guidelines are formulated and regularly updated by multidisciplinary teams consisting of leading experts across all types of tumors nationwide. They currently encompass a comprehensive diagnostic and treatment system covering almost all common tumors, including lymphoma and malignant tumors, as well as some rare cancers. As a unified reference followed by medical institutions at all levels nationwide, the CSCO guidelines also serve as a core reference for adjustments to the national medical insurance drug list, new drug clinical development, and market approval. The level of recommendation directly reflects the clinical value and authoritative recognition of the treatment options.

29K Views